Ligand Pharmaceuticals (LGND) Retained Earnings (2010 - 2026)

Ligand Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting $5.4 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at $5.4 million, up 444.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 444.85% YoY), and the FY2025 annual result was $608.1 million, up 10333.73% from the prior year.
• Retained Earnings came in at $5.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $608.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $608.1 million in Q4 2025 to a low of -$5.9 million in Q4 2024.
• The 5-year median for Retained Earnings is $8.5 million (2025), against an average of $242.0 million.
• Across the five-year window, Retained Earnings soared 54448.78% in 2022 and plunged 101.18% in 2024, its largest moves.
• Ligand Pharmaceuticals' Retained Earnings stood at $450.9 million in 2022, then rose by 11.57% to $503.0 million in 2023, then slumped by 101.18% to -$5.9 million in 2024, then jumped by 10333.73% to $608.1 million in 2025, then tumbled by 99.11% to $5.4 million in 2026.
• The last three Retained Earnings figures came in at $5.4 million (Q1 2026), $608.1 million (Q4 2025), and $578.2 million (Q3 2025), per Business Quant data.